[go: up one dir, main page]

ATE223230T1 - Pulmonäre verabreichung des löslichen komplement- receptors typ 1 scr1 - Google Patents

Pulmonäre verabreichung des löslichen komplement- receptors typ 1 scr1

Info

Publication number
ATE223230T1
ATE223230T1 AT94909571T AT94909571T ATE223230T1 AT E223230 T1 ATE223230 T1 AT E223230T1 AT 94909571 T AT94909571 T AT 94909571T AT 94909571 T AT94909571 T AT 94909571T AT E223230 T1 ATE223230 T1 AT E223230T1
Authority
AT
Austria
Prior art keywords
complement
scr1
receptor type
pulmonary administration
complement receptor
Prior art date
Application number
AT94909571T
Other languages
English (en)
Inventor
James L Levin
Jean F Regal
Carol A Toth
Original Assignee
Avant Immunotherapeutics Inc
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avant Immunotherapeutics Inc, Univ Minnesota filed Critical Avant Immunotherapeutics Inc
Application granted granted Critical
Publication of ATE223230T1 publication Critical patent/ATE223230T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
AT94909571T 1993-02-12 1994-02-08 Pulmonäre verabreichung des löslichen komplement- receptors typ 1 scr1 ATE223230T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1691893A 1993-02-12 1993-02-12
PCT/US1994/001405 WO1994017822A1 (en) 1993-02-12 1994-02-08 PULMONARY ADMINISTRATION OF sCR1 AND OTHER COMPLEMENT INHIBITORY PROTEINS

Publications (1)

Publication Number Publication Date
ATE223230T1 true ATE223230T1 (de) 2002-09-15

Family

ID=21779735

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94909571T ATE223230T1 (de) 1993-02-12 1994-02-08 Pulmonäre verabreichung des löslichen komplement- receptors typ 1 scr1

Country Status (8)

Country Link
US (1) US6169068B1 (de)
EP (1) EP0682526B1 (de)
JP (1) JP3689422B2 (de)
AT (1) ATE223230T1 (de)
AU (1) AU685433B2 (de)
CA (1) CA2155933C (de)
DE (1) DE69431290D1 (de)
WO (1) WO1994017822A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
AUPM411494A0 (en) * 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
EP0833667A4 (de) * 1995-06-07 2001-11-21 Univ California Stabilisierung von polynukleotidkomplexen
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
US6166288A (en) * 1995-09-27 2000-12-26 Nextran Inc. Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
US20040014650A1 (en) * 2002-07-17 2004-01-22 Sheppard Paul D Methods for enhancing wound repair
AU6110301A (en) 2000-04-29 2001-11-12 Univ Iowa Res Found Diagnostics and therapeutics for macular degeneration-related disorders
ATE420630T1 (de) * 2000-11-29 2009-01-15 Itoham Foods Inc Pulverzubereitungen und verfahren zu ihrer herstellung
US20020198139A1 (en) * 2001-05-17 2002-12-26 Deutschman Clifford S. Method of preventing acute pulmonary cell injury
JP2004087560A (ja) 2002-08-23 2004-03-18 Sansha Electric Mfg Co Ltd 電源装置
WO2004103294A2 (en) 2003-05-15 2004-12-02 Tanox, Inc. Methods and compositions for the prevention and treatment of sepsis
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US20060039870A1 (en) * 2004-08-20 2006-02-23 Turner Jeffrey D Pulmonary delivery of enzymatic medical countermeasures
US20070004625A1 (en) * 2005-06-30 2007-01-04 Li Liang-Man Use of complement inhibitory proteins to treat spinal cord injury
EP1738763A1 (de) * 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Verwendung eines Komplement-inhibierenden Proteins zur Behandlung von Rückenmarksverletzungen
US8340944B2 (en) * 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20080004905A1 (en) * 2006-06-28 2008-01-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for analysis of nutraceutical associated components
US20080033763A1 (en) * 2005-11-30 2008-02-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems related to receiving nutraceutical associated information
US20070124176A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20080114577A1 (en) * 2005-11-30 2008-05-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems associated with nutraceutical related assays
US20070124219A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized nutraceutical selection and packaging
US20110145009A1 (en) * 2005-11-30 2011-06-16 Jung Edward K Y Methods and systems related to transmission of nutraceutical associatd information
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US10296720B2 (en) * 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US20080052114A1 (en) * 2005-11-30 2008-02-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods related to nutraceuticals
US20070174128A1 (en) * 2005-11-30 2007-07-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20070136092A1 (en) * 2005-11-30 2007-06-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20080210748A1 (en) * 2005-11-30 2008-09-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware, Systems and methods for receiving pathogen related information and responding
US20070289258A1 (en) * 2006-06-14 2007-12-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Individualized pharmaceutical selection and packaging
US7927787B2 (en) * 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US7827042B2 (en) * 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
KR101513308B1 (ko) 2006-03-08 2015-04-28 아케믹스 엘엘씨 안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제
US8580735B2 (en) 2007-02-05 2013-11-12 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
WO2009014633A1 (en) * 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
EP2077132A1 (de) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Abgabevorrichtung, Aufbewahrungsvorrichtung und Verfahren zur Abgabe einer Formulierung
EP2352517A4 (de) 2008-11-10 2013-01-16 Alexion Pharma Inc Verfahren und zusammensetzungen zur behandlung von komplementassoziierten erkrankungen
EP2662472B1 (de) 2009-03-31 2019-02-27 Boehringer Ingelheim International Gmbh Verfahren zur Beschichtung einer Oberfläche eines Bauteils
WO2010133294A2 (de) 2009-05-18 2010-11-25 Boehringer Ingelheim International Gmbh Adapter, inhalationseinrichtung und zerstäuber
WO2011064164A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
EP2504051B1 (de) 2009-11-25 2019-09-04 Boehringer Ingelheim International GmbH Zerstäuber
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
EP2585151B1 (de) 2010-06-24 2018-04-04 Boehringer Ingelheim International GmbH Vernebler
CN103237557A (zh) * 2010-09-15 2013-08-07 赛尔戴克斯治疗公司 用可溶性I型补体受体(sCR1)治疗慢性肾病
WO2012058479A2 (en) * 2010-10-27 2012-05-03 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type i (scr1)
EP2694220B1 (de) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
ES2650917T3 (es) 2013-08-07 2018-01-23 Alexion Pharmaceuticals, Inc. Proteínas biomarcadoras del síndrome urémico hemolítico atípico (SUHA)
WO2015018904A1 (en) 2013-08-09 2015-02-12 Boehringer Ingelheim International Gmbh Nebulizer
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
DK3139984T3 (da) 2014-05-07 2021-07-19 Boehringer Ingelheim Int Forstøver
WO2015169732A1 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Container, nebulizer and use
PL3139981T3 (pl) 2014-05-07 2021-06-14 Boehringer Ingelheim International Gmbh Nebulizator

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US5093316A (en) 1986-12-24 1992-03-03 John Lezdey Treatment of inflammation
IL89790A (en) 1988-04-01 2002-05-23 Johns Hopking University Sequences of nucleic acids encoding and cells producing CR1 protein and methods for its production and purification
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
GB8808701D0 (en) * 1988-04-13 1988-05-18 Erba Carlo Spa Beta-lactam derivatives
US5011678A (en) 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
AU9149791A (en) * 1990-12-06 1992-07-08 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
US5833989A (en) * 1992-06-24 1998-11-10 Adprotech Plc Soluble CR1 derivatives

Also Published As

Publication number Publication date
WO1994017822A1 (en) 1994-08-18
EP0682526B1 (de) 2002-09-04
CA2155933A1 (en) 1994-08-18
AU685433B2 (en) 1998-01-22
JPH08511506A (ja) 1996-12-03
EP0682526A1 (de) 1995-11-22
JP3689422B2 (ja) 2005-08-31
CA2155933C (en) 2000-04-04
EP0682526A4 (de) 1996-03-06
DE69431290D1 (de) 2002-10-10
AU6237294A (en) 1994-08-29
US6169068B1 (en) 2001-01-02

Similar Documents

Publication Publication Date Title
ATE223230T1 (de) Pulmonäre verabreichung des löslichen komplement- receptors typ 1 scr1
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
SE9302308L (sv) Proteinberedning
IT1241996B (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
MD960288A (ro) Metodă de separare a formelor DNazei, DNaza omului, compoziţie farmaceutică, metodă de păstrare a DNazei, metodă de tratare
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
DE69218948D1 (de) IGF-I zur Verbesserung der neuronale Lage
WO1997049373A3 (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
DE69429832D1 (de) Verfahren zur behandlung von festhaltenden lungensekreten
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
PL309604A1 (en) Pharmaceutical composition for treating nicotin dependence
ATE169225T1 (de) Anwendung von urodilatin bei lungen- und bronchialerkrankungen
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
YU64192A (sh) Analozi insulina
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
MX9800686A (es) Nueva proteina hmw humana mp52s.
TW207496B (en) Pharmaceutical composition for preventing or delaying the occurrence of dementia
MY111155A (en) Medicaments

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties